Lakefront Biotherapeutics NV(LKFT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 35 days
PROFIT SINCE LAST BUY
+13.87% ▲
LAST CLOSE
$33.98
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for LKFT

11/13/2026: LKFT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Lakefront Biotherapeutics NV is a clinical-stage biopharmaceutical company specializing in immunology and inflammation therapies, operating under its newly reset corporate identity. The company's primary strength lies in its exceptionally robust cash position and its focused pipeline anchored by lead asset gamgertamig. Its core investment story revolves around advancing targeted autoimmune treatments and strategically deploying capital toward high-potential clinical opportunities. Key risks include clinical trial execution uncertainties, regulatory hurdles, and intense competition in the biopharmaceutical sector. The stock suits growth-oriented or momentum investors comfortable with biotechnology risk, requiring close monitoring of upcoming clinical data readouts and pipeline developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers potential clinical-stage growth catalysts driven by its specialized immunology pipeline, balanced by a transitional business model.
Momentum investorStrong fit while signal remains positiveTechnical breakouts and positive clinical trial updates can trigger strong short-term upward momentum.
Value investorMixed fitSubstantial cash reserves relative to market capitalization provide asset backing, though lack of commercial earnings limits traditional value metrics.
Dividend investorWeak fitThe company does not pay dividends, focusing entirely on clinical development and capital allocation.
Low-risk investorWeak fitClinical-stage biotechnology stocks carry inherent binary clinical trial and regulatory risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stock prices frequently fluctuate in response to clinical data releases and market sentiment shifts.
Valuation riskMediumValuation relies heavily on pipeline potential and cash backing rather than immediate product sales.
Competition risk (immunology biotherapeutics)HighNumerous large competitors are actively developing alternative treatments for autoimmune and inflammatory diseases.
Business qualityMediumThe company benefits from exceptional financial liquidity but is currently transitioning its operating scope.
Dividend incomeLow / noneNo dividend distributions are currently provided to shareholders.
Execution riskHighSuccess depends on successfully executing clinical trials and advancing pipeline assets through regulatory approvals.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.24B USD
Price to earnings Ratio 2.44
1Y Target Price 30.41
Price to earnings Ratio 2.44
1Y Target Price 30.41
Volume (30-day avg) 280.3K shares
Beta 0.01
52 Weeks Range 25.68 - 36.24
Updated Date 11/15/2026
52 Weeks Range 25.68 - 36.24
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 13.94

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Flat / Range-Bound
PRICE PATH

Flat / Range-Bound

The stock price has been trading within a narrow range with minimal directional movement.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit -11.76%
Avg. Invested days 37
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
LKFT receives a 4-star rating, supported by solid company fundamentals, and solid quantitative characteristics. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
LKFT has solid overall fundamentals (4 stars), with solid financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+333.1%) and strong revenue growth (+303.5%) are partially offset by weak cash generation (FCF margin -24.4%).

Financial Health Rating

★★★★★
LKFT's financial health is supported by solid profitability, including gross margin of 97.3% and operating margin of 45.1%. Cash strength is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is LKFT's strongest growth driver at +333.1% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+303.5%, strong) and free-cash-flow growth (+32.5%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 24.1% and approximately 700.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 26.43% supports management-shareholder alignment.

Top 5 Institutional Investors

TANG CAPITAL MANAGEMENT LLC 5.75%
Madison Avenue Partners, LP 5.23%
Prosight Management, LP 3.03%
EcoR1 Capital, LLC 2.53%
Ameriprise Financial Inc 1.93%

Unit Economics (Per $1K Revenue)

★★★★★
LKFT generates approximately $973 of gross profit, $451 of operating income, and $-244 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins and weak cash conversion support a 3-star rating, while capital efficiency is solid.

Economic Dimensions

★★★★★
Effective Tax Rate: -6.19% (Tax Credit)

Quantitative Style Profile

★★★★★
LKFT has a high-quality, liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Immunology Therapeutics & LicensingFuture commercialization milestones, product sales, and collaborative licensing revenues derived from clinical-stage assets like gamgertamig.Revenue generation currently depends on clinical development progress, partnership agreements, and eventual product approvals rather than steady commercial sales.

Valuation

Trailing PE 2.44
Forward PE 344.83
Enterprise Value -211.34M
Price to Sales(TTM) 2.26
Enterprise Value -211.34M
Price to Sales(TTM) 2.26
Enterprise Value to Revenue -
Enterprise Value to EBITDA -31.5
Shares Outstanding 65.90M
Shares Floating 461.79M
Shares Outstanding 65.90M
Shares Floating 461.79M
Percent Insiders 26.43
Percent Institutions 24.14

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.